Mr. Pratap Sandhu reports

THE PRECISION PEPTIDE COMPANY (BPC) LEAD PRODUCT ACHIEVES 95.5% PURITY IN INDEPENDENT LAB TESTING, CLEARING THE INDUSTRY BENCHMARK AND ADVANCING TOWARD COMMERCIAL LAUNCH

The Precision Peptide company Inc. has released initial third party test results for its needle-free BPC-157 transdermal patch, the company's lead product candidate.

Highlights

• The BPC-157 patch is a wearable, needle-free product, designed to remove the injection barrier that has historically limited consumer adoption of peptide products.
• Results support The Precision Peptide Company's continued progression of its lead product toward commercial launch.
• Independent lab results confirm 95.5-per-cent chromatographic purity and a quantified 2.02-milligram dose of BPC-157 per patch.
• Purity result clears the greater than or equal to 95-per-cent threshold recognized across the peptide industry as the analytical benchmark for credible high-purity-grade peptide products.
• Testing performed by independent U.S. analytical laboratory Miraxis Labs (San Diego, Calif.), using ultrahigh performance liquid chromatography with diode array detection (UHPLC-DAD) and certified by two PhD scientists.

The results

Independent analytical laboratory Miraxis Labs, based in San Diego, Calif., has tested the patch and confirmed:

• 95.5-per-cent chromatographic purity;
• 2.02 mg of BPC-157 per patch (quantified potency).

Both results were measured using Ultra High-Performance Liquid Chromatography with Diode Array Detection (UHPLC-DAD). The results were certified by Dr. David Marelius, PhD (chief scientific officer of Miraxis Labs), and Dr. Erik Paulson, PhD (lab director). The full certificate of analysis is publicly available via Miraxis Labs' verification portal.

The results in context

The 95.5-per-cent purity result clears the recognized industry benchmark for credible peptide products. Industry guidance and laboratory standards widely identify greater than or equal to 95 per cent chromatographic purity as the analytical threshold for credible high-purity grade peptide products.

The 2.02 mg quantified dose per patch confirms that the amount of BPC-157 in each patch is precisely measurable, using the industry-standard analytical method for peptide quantification (UHPLC-DAD).

The results were generated independently and are publicly verifiable. The company believes these results support the continued progression of the patch toward commercial release and position the company as a quality-first operator in a category in which independent third party verification has not yet become standard practice.

The product

The patch is the company's lead product candidate. It is designed to deliver BPC-157 through the skin via a wearable patch, eliminating the need for injections, reconstitution, sterile handling or dose measurement.

Research has consistently identified needle aversion as a leading barrier to therapies that consumers would otherwise consider, and adoption of peptide products has historically skewed toward biohackers, athletes and clinical populations already comfortable with self-administered injectables. The patch is designed to remove that barrier entirely.

Regulatory context

In February, 2026, the U.S. Department of Health and Human Services announced that BPC-157 would be among several peptides moving back toward Category 1 status, subject to ongoing review. The U.S. Food and Drug Administration's pharmacy compounding advisory committee is scheduled to formally evaluate BPC-157 (free base and acetate forms) for inclusion on the 503A Bulks List at its public meeting on July 23, 2026. The company believes this regulatory transition, combined with growing scrutiny of offshore and grey market suppliers, creates an opportunity for operators with credentialed, independently verified product data.

Pratap Sandhu, CEO of the company, commented: "This is a milestone result. We set ourselves a high standard on this product: independent third party testing, a measured dose per patch and a purity result that clears the recognized industry benchmark. Miraxis Labs has confirmed all three. This is the moment the BPC-157 patch goes from a product in testing to a product with credentialed analytical data behind it, and it brings us materially closer to commercial release of our lead product."

Justin Kirkland, chief scientific officer of Amino Innovations, added: "Delivering BPC-157 in a wearable patch at this level of purity is a meaningful piece of formulation work. The 95.5-per-cent purity result and the 2.02 mg measured dose per patch, both confirmed by independent UHPLC-DAD testing, are the data points that matter for a commercially credible peptide product. These results give us strong confidence in the patch as a credible, scalable alternative to traditional peptide administration."

Next steps

Subject to the satisfactory completion of additional testing, manufacturing scale-up and applicable regulatory considerations, the company intends to progress the patch toward commercial release as part of its broader transdermal peptide platform under Amino Innovations. Further updates regarding product launch timing, additional pipeline products and broader commercialization initiatives are expected to be announced in subsequent updates.

About The Precision Peptide Company Inc.

The Precision Peptide is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.

We seek Safe Harbor.